Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

North American Insulin Therapeutics Market (2018-2023): CAGR to Grow at 8% - ResearchAndMarkets.com

Research and Markets
Posted on: 19 Oct 18

The "North America Insulin Therapeutics Market - Segmented by Product Type, Drug Type, Disease Indication, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The North American insulin therapeutics market is expected to register a CAGR of 8% during the forecast period 2018-2023. The United States dominates the market, due to growing prevalence of diabetes and obesity in the country.

Growing Diabetes Prevalence in North America

The United States is the major consumer of insulin drugs, globally, owing to growing awareness of diabetes among the population, high healthcare expenditure, and adoption of advance therapeutics (biosimilars) in the countries.

However, Mexico and Canada are anticipated to expand significantly during forecast period, owing to rising rate of obesity, growing government initiatives in cure of chronic diseases in the countries, and genetic factors for Type 2 diabetes, which are likely to augment the insulin therapeutics market in North America.

Thus, increasing prevalence of diabetes across the North American region will surge a huge demand for insulin, which will drive the market for insulin therapeutics.

Key Highlights

  • Increasing Pricing Pressure & Expiration of Patents
  • Mexico to Grow at a High CAGR

Notable Developments in the Market

  • Novo Nordisk A/S launched Xultophy 100/3.6 (insulin degludec and liraglutide injection) in the United States.
  • Merck Co. Inc. and Pfizer Inc. received US Food and Drug Administration (FDA) approval for STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

Companies Featured

  • Astrazeneca
  • Biocon
  • Bioton S.A.
  • Eli Lilly & Company
  • Julphar
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi-Aventis
  • Wockhardt Ltd.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/hq6jxj/north_american?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005532/en/

Business Wire
www.businesswire.com

Last updated on: 19/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.